Key Drivers
- High profitability
- Robust FCF
- Tight liquidity
AIAI Summary
AstraZeneca has shifted from a defensive large‑cap pharma into an execution‑dependent growth story—its upside now hinges on delivering mid‑to‑late‑stage oncology readouts, efficiently scaling the $50bn U.S. manufacturing/commercial buildout, and integrating recent M&A/AI assets to convert strong margins and FCF into sustained revenue growth. Monitor upcoming Phase III readouts, FCF conversion vs. rising capex, and commercialization KPIs (and a break below ~$183) as concrete triggers that will validate or rapidly reverse the premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Robust FCF
- •Tight liquidity
AZN delivers high margins, strong returns and robust free cash flow funding dividends and R&D, but faces tight near‑term liquidity, material net leverage and rich valuation.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support cluster broken
- •Resistance near $208
Over the last month the stock dropped ~10% from $204.20 to $183.60, breaking the $201–$195 support cluster, establishing immediate support at $183–$186 and resistance around $205–$208 (peak $208.45), signaling a clear short-term downtrend with elevated volatility.
Broke the $201–$195 congestion zone mid‑March, triggering a ~10% decline and elevated range (~12–13%)
Sentiment & News
Key News Insights:
- •Imfinzi EU approval
- •Shanghai cell hub
- •Analyst upgrades
Mid‑March headlines show AstraZeneca expanding oncology approvals and China cell‑therapy capacity while analysts turned bullish, price momentum improved and institutional trading was mixed amid active M&A interest. #M&A
These moves strengthen AZN's growth narrative and share‑momentum but leave potential upside tied to successful execution and M&A outcomes
Similar Companies in Healthcare
Other companies in the same sector with AI ratings